Group Lead, AOC (Extrahepatic)

SGInnovate; Singapore; On-site; SGD 180,000 - 300,000; Full time

Job summary

NATi seeks a Group Leader to build and lead an interdisciplinary team developing antibody-oligonucleotide conjugates (AOCs) for extrahepatic delivery. You will own the scientific strategy for the AOC platform and drive program milestones in a fast-moving environment.

Lead antibody discovery, conjugation chemistry, and developability workflows, partnering with oligo chemistry, DMPK, and bioanalytics to enable asset generation beyond hepatic indications.

Qualifications

• A doctorate degree in Protein Engineering, Chemical Biology, Bioconjugation Chemistry, Organic/Medicinal Chemistry, or related field.
• Minimum of +8 (Sr. Scientist) or +12 (Principal Scientist) years of relevant experience.
• Proven track record in antibody discovery/engineering and bioconjugation with program ownership.
• Ability to lead cross-functional teams in a matrix environment.
• IP, publications, IND filings, or other public disclosures.

Responsibilities

• Define AOC design principles for extrahepatic delivery.
• Drive program strategy, milestones, and decision frameworks.
• Lead multi-disciplinary project teams and governance reviews.
• Oversee antibody generation, screening, and selection across platforms.
• Establish developability workflows (expression, purification, stability, CQAs).
• Own the bioconjugation strategy and collaborate with oligo chemists.

Skills

Leadership

Antibody discovery

Bioconjugation chemistry

Analytical methods

Education

Doctorate in Protein Engineering or related field

Tools

Bioconjugation platforms

Linker chemistry

Analytical characterization

Job description

NATi seeks a Group Leader to build and lead an interdisciplinary team developing antibody-oligonucleotide conjugates (AOCs) for extrahepatic delivery. You will own the scientific strategy for the AOC platform and drive program milestones in a fast-moving environment.

Lead antibody discovery, conjugation chemistry, and developability workflows, partnering with oligo chemistry, DMPK, and bioanalytics to enable asset generation beyond hepatic indications.